Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03482297
Other study ID # 151008
Secondary ID 1R01HL144568-01A
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date March 1, 2018
Est. completion date December 1, 2024

Study information

Verified date March 2024
Source Vanderbilt University Medical Center
Contact Bonnie K Black, RN
Phone 615-343-6862
Email autonomics@vumc.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The automated inflatable abdominal binder is an investigational device for the treatment of orthostatic hypotension (low blood pressure on standing) in patients with autonomic failure. The purpose of this study is to determine safety and effectiveness of the automated abdominal binder in improving orthostatic tolerance in these patients.


Description:

This is a randomized, double-blind, sham-controlled, parallel group study to compare the efficacy of the automated abdominal binder (inflated to 40 mm Hg) versus sham treatment (abdominal binder inflated to 5 mm Hg) in improving orthostatic tolerance in patients with primary autonomic failure disabled by orthostatic hypotension. Potential participants will be admitted to the Vanderbilt Clinical Research Center for evaluation of inclusion and exclusion criteria. Eligible patients will be randomized to the active or sham binder group. Patients will then be asked to participate on three separate study days, two days apart: one day for baseline measurements (placebo pill t.i.d), one day for treatment with 10 mg midodrine t.i.d (standard of care), and one day for treatment with active or sham binder combined with placebo pill t.i.d. The order of the study days will be randomized. On each study day, blood pressure and heart rate will be measured while sitting, lying down, standing and walking during the Morning Orthostatic Trial, and posture and walking tests.


Recruitment information / eligibility

Status Recruiting
Enrollment 31
Est. completion date December 1, 2024
Est. primary completion date September 1, 2024
Accepts healthy volunteers No
Gender All
Age group 40 Years to 80 Years
Eligibility Inclusion Criteria: - Male and female subjects, age 40-80 years. - Possible or probable Multiple Systems Atrophy and Pure Autonomic Failure as defined by Consensus Criteria. - Neurogenic orthostatic hypotension defined as a =30-mm Hg decrease in SBP within 3 minutes of standing associated with impaired autonomic reflexes determined by autonomic testing in the absence of other identifiable causes, and - Moderate to severe orthostatic symptoms, defined as an Orthostatic Hypotension Symptom Assessment (OHSA) composite score =4 (self-rating Likert scale of 0 to 10, with 0 reflecting absence of symptoms), within the first 10 minutes of the screening orthostatic stress test, and that have an impact in quality of life, as defined by the patient. - Able and willing to provide informed consent. Exclusion Criteria: - Pregnancy. - Systemic illnesses known to produce autonomic neuropathy, including but not limited to diabetes mellitus, amyloidosis, monoclonal gammopathies, and autoimmune neuropathies. - History of known aortic aneurisms, thoracic, abdominal or pelvic surgery in the past 6 months; symptomatic abdominal or inguinal hernias; severe gastroesophageal reflux; recent fractures or fissures of ribs, thoracic or lumbar spine; medical devices implanted on the abdominal wall or abdomen that would interfere with the binder; known abdominal or pelvic tumors, cysts or enlarged spleen; intolerance to any increase in intraabdominal pressure. - Pre-existing sustained supine hypertension =180/110. - Bedridden patients or those who are unable to stand due to motor impairment or severe orthostatic hypotension. - Clinically unstable coronary artery disease (recurrent angina despite medical therapy), or major cardiovascular or neurological event in the past 6 months (myocardial infarction, stroke or transient ischemic attacks). - Concomitant use of anticoagulants

Study Design


Intervention

Device:
automated abdominal binder
The binder automatically inflates every time the participant stands up to apply a compression level of about 40 mmHg. Participants will wear the device throughout the active/sham study day.
Sham binder
The binder automatically inflates every time the participant stands up to apply a compression level of about 5 mmHg. Participants will wear the device throughout the active/sham study day.
Drug:
Placebo
Oral placebo will be given three times a day on the baseline day (placebo)
Midodrine
A midodrine pill 10mg will be given three times a day on the standard of care study day

Locations

Country Name City State
United States Autonomic Dysfunction Center/ Vanderbilt University Medical Center Nashville Tennessee

Sponsors (2)

Lead Sponsor Collaborator
Vanderbilt University Medical Center National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Orthostatic tolerance orthostatic tolerance is defined as the area under the curve of the upright systolic blood pressure (AUCSBP) during the Morning Orthostatic Trials After 10 minutes of standing (or as tolerated) during the Morning orthostatic trial on the automated binder/sham study day
Primary Orthostatic Hypotension Symptom Assessment (OHSA) Score The Orthostatic Hypotension Symptom Assessment (OHSA) Score is the part I of the Orthostatic Hypotension Questionnaire (OHQ). It consists of six questions, each rating the intensity of one characteristic symptom of orthostatic hypotension: 1. Dizziness, lightheadedness, feeling faint, or feeling like you might black out; 2. Problems with vision (blurring, seeing spots, tunnel vision, etc.); 3. Generalized weakness; 4. Fatigue; 5. Trouble concentrating; and 6. Head/neck discomfort.The items are scored on an 11-point Likert scale from 0 to 10, with 0 indicating no symptoms and 10 indicating the worst possible symptoms. Composite score is the average of the item scores obtained at the post-intervention stand period during the Morning Orthostatic Trials After 10 minutes of standing (or as tolerated) during the Morning orthostatic trial on the automated binder/sham study day
Secondary Upright time Sum of standing and walking times After 10 minutes of standing and 15 minutes waking (as tolerated)
See also
  Status Clinical Trial Phase
Completed NCT03593512 - Deep Brain Stimulation for Autonomic and Gait Symptoms in Multiple System Atrophy N/A
Recruiting NCT03648905 - Clinical Laboratory Evaluation of Chronic Autonomic Failure
Active, not recruiting NCT05699460 - Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
Recruiting NCT02897063 - Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure Phase 1
Not yet recruiting NCT00758849 - Fipamezole in Neurogenic Orthostatic Hypotension Phase 2
Completed NCT01155492 - Increased Gut Permeability to Lipopolysaccharides (LPS) in Parkinson's Disease N/A
Recruiting NCT04431713 - Exenatide Once-weekly as a Treatment for Multiple System Atrophy Phase 2
Completed NCT04184063 - Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA) Phase 2
Recruiting NCT05121012 - Synaptic Loss in Multiple System Atrophy
Terminated NCT03589976 - A Futility Trial of Sirolimus in Multiple System Atrophy Phase 2
Recruiting NCT04706234 - Systematic Assessment of Laryngopharyngeal Function in Patients With MSA, PD, and 4repeat Tauopathies
Completed NCT00368199 - Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes N/A
Recruiting NCT04472130 - Neurodegenerative Diseases Registry
Recruiting NCT04876326 - Potential Use of Autologous and Allogeneic Mesenchymal Stem Cells in Patients With Multiple System Atrophy N/A
Recruiting NCT04680065 - GDNF Gene Therapy for Multiple System Atrophy Phase 1
Completed NCT03753763 - Safinamide for Multiple System Atrophy (MSA) Phase 2
Recruiting NCT04250493 - Insulin Resistance in Multiple System Atrophy N/A
Recruiting NCT06072105 - Medical Decision Making in Multiple System Atrophy N/A
Terminated NCT02149901 - Water and Sudafed in Autonomic Failure Early Phase 1
Terminated NCT00997672 - Lithium in Multiple System Atrophy Phase 2